– UK, Glasgow – Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins, today announced the closing of a USD $7.5m Series A funding round led by Advent Life Sciences.…
– USA, CA – Moximed®, Inc., developer of unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA), announced today an oversubscribed Series C round of $50MM with new investors Advent Life Sciences and Future Fund joining existing investors NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex Healthcare.…
– USA, MA – Arrakis Therapeutics, a pioneering biopharmaceutical company, has completed a $38 million Series A financing led by Canaan Partners with participation by Advent Life Sciences, Pfizer Inc.,…
– UK, Stevenage – NeRRe Therapeutics, a clinical-stage company developing a unique portfolio of neurokinin receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity, announced it has raised £23 million in an oversubscribed Series B financing round.…
– USA, FL – Vestagen Technical Textiles, Inc., a medical technology company developing and marketing high performance apparel for healthcare and other demanding applications, today announced it has named Bill Bold Chief Executive Officer.…